The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with FSGS. The intention is to evaluate drug safety, as well as to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio, which is a marker of kidney damage). PF-06730512 works as an antagonist, meaning it possibly reduces a biologic activity that is associated with FSGS. PF-06730512 has been designed to affect the podocyte, which, when working properly, is associated with normal kidney function. Patients will participate for about 8.5 months, and will receive the study drug by intravenous infusion every 2 weeks over a 12 week period.
How To Contact a Study Center: